{"nctId":"NCT01810939","briefTitle":"A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)","startDateStruct":{"date":"2013-02"},"conditions":["Chronic Kidney Disease (CKD)","Hyperkalemia (HK)"],"count":243,"armGroups":[{"label":"Patiromer","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Patiromer"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Patiromer","otherNames":["RLY5016 for Oral Suspension","Veltassa"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and females ages 18 - 80\n* Chronic kidney disease (CKD) - eGFR 15 to \\< 60 mL/min/1.73m2 at screening\n* Hyperkalemia, defined as a serum potassium value of 5.1 to \\< 6.5 mEq/L at screening\n* Taking either an Angiotensin-Converting Enzyme (ACE) Inhibitor, an Angiotensin II receptor blocker (ARB), or an aldosterone antagonist (AA) medication\n* Informed consent given\n\nExclusion Criteria:\n\n* Participants with auto-immune related chronic kidney disease such as lupus nephritis or renal scleroderma/scleroderma renal crisis, or mixed connective tissue disease with renal involvement\n* Participants with uncontrolled Type 1 diabetes, defined as or a HbA1c \\> 10.0 %, or hospitalization to treat hyper- or hypo-glycemia in the past 3 months within the previous 6 months in participants with Type 2 diabetes\n* Participants with severe heart failure, defined as NYHA (New York Heart Association) class IV\n* Participants with major surgery including thoracic and cardiac, in the past 3 months, or participants with heart or kidney transplant\n* Participants with significant cardiovascular or cerebrovascular events in the past 2 months, such as cardiac arrest, myocardial infarction, or stroke\n* Participants with BMI ≥ 40 kg/m2","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Proportion of Participants With Serum Potassium Levels in the Target Range of 3.8 to < 5.1 mEq/L at Part A Week 4","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With Serum Potassium That Was ≥ 5.5 mEq/L in Part B","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With Serum Potassium ≥ 5.1 mEq/L in Part B","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Serum Potassium From Part A Baseline to Part A Week 4","description":"The primary analysis endpoint is the change from Baseline at Week 4. The estimate of the change at Week 4 is from a repeated measures model, which includes data from Weeks 1, 2, 3 and 4. The analysis includes all intent to treat participants who had a serum potassium result at baseline and at least one weekly post-baseline visit (i.e. Part A Week 1 or later) and excludes six participants who had no result collected after Day 3).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.01","spread":"0.031"}]}]}]},{"type":"PRIMARY","title":"Change in Serum Potassium From Part B Baseline","description":"Change in Serum Potassium from Part B Baseline to either:\n\nPart B Week 4 visit, if the participant's serum potassium remained ≥ 3.8 mEq/L and \\< 5.5 mEq/L up to the Part B Week 4 visit or the earliest Part B visit at which the participant's serum potassium was \\< 3.8 mEq/L or ≥ 5.5 mEq/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":243},"commonTop":["Constipation","Headache","Hypertension","Influenza"]}}}